1. Home
  2. VALU vs GLUE Comparison

VALU vs GLUE Comparison

Compare VALU & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VALU
  • GLUE
  • Stock Information
  • Founded
  • VALU 1931
  • GLUE 2019
  • Country
  • VALU United States
  • GLUE United States
  • Employees
  • VALU N/A
  • GLUE N/A
  • Industry
  • VALU Investment Managers
  • GLUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • VALU Finance
  • GLUE Health Care
  • Exchange
  • VALU Nasdaq
  • GLUE Nasdaq
  • Market Cap
  • VALU 345.7M
  • GLUE 351.2M
  • IPO Year
  • VALU N/A
  • GLUE 2021
  • Fundamental
  • Price
  • VALU $37.90
  • GLUE $4.67
  • Analyst Decision
  • VALU
  • GLUE Buy
  • Analyst Count
  • VALU 0
  • GLUE 2
  • Target Price
  • VALU N/A
  • GLUE $13.50
  • AVG Volume (30 Days)
  • VALU 5.3K
  • GLUE 376.6K
  • Earning Date
  • VALU 09-12-2025
  • GLUE 08-07-2025
  • Dividend Yield
  • VALU 3.36%
  • GLUE N/A
  • EPS Growth
  • VALU 8.91
  • GLUE N/A
  • EPS
  • VALU 2.20
  • GLUE 0.29
  • Revenue
  • VALU $35,079,000.00
  • GLUE $177,986,000.00
  • Revenue This Year
  • VALU N/A
  • GLUE $83.76
  • Revenue Next Year
  • VALU N/A
  • GLUE N/A
  • P/E Ratio
  • VALU $17.66
  • GLUE $15.87
  • Revenue Growth
  • VALU N/A
  • GLUE 2990.57
  • 52 Week Low
  • VALU $32.94
  • GLUE $3.50
  • 52 Week High
  • VALU $57.68
  • GLUE $12.40
  • Technical
  • Relative Strength Index (RSI)
  • VALU 48.80
  • GLUE 48.58
  • Support Level
  • VALU $37.11
  • GLUE $4.54
  • Resistance Level
  • VALU $38.85
  • GLUE $4.92
  • Average True Range (ATR)
  • VALU 1.03
  • GLUE 0.23
  • MACD
  • VALU 0.01
  • GLUE 0.04
  • Stochastic Oscillator
  • VALU 58.46
  • GLUE 69.18

About VALU Value Line Inc.

Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: